Mounjaro®
Starting from £179.99/mo
Start journey Learn moreBloating is one of the most commonly reported side effects of Wegovy (semaglutide), and the trial data explains why: in the STEP 1 study, gastrointestinal symptoms affected a significant proportion of participants, particularly in the early weeks of treatment and after each dose increase. Wegovy slows the rate at which your stomach empties, which is central to how it reduces appetite — but that same mechanism can leave food sitting longer in the gut, causing gas, discomfort and that heavy, distended feeling many people describe. It is a prescription-only medicine, and a prescriber will assess your full picture before treatment begins. For most people, bloating settles as the body adjusts; understanding what drives it, and what can ease it, makes that adjustment period considerably easier.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults over 68 weeks and remains the central evidence base for Wegovy at the 2.4mg maintenance dose. Nausea was the most frequently reported side effect, but bloating, gas, constipation and indigestion appeared consistently throughout the dose-escalation phase. The pattern was clear: symptoms clustered around the weeks immediately after starting and again after each upward dose step, then gradually settled. That is not a coincidence — it reflects the biology directly.
Semaglutide activates GLP-1 receptors in the gut and brain, reducing appetite and slowing gastric emptying. Slower gastric emptying means food lingers longer before passing into the small intestine. For the gut, particularly in the early weeks, this is unfamiliar. Fermentation of food sitting in the upper digestive tract produces gas. The result is bloating, often worse after larger meals or foods that are already known to cause gas. The NHS medicines page for semaglutide lists bloating, burping and indigestion alongside nausea as common side effects, noting they typically improve as treatment continues.
For most people, the adjustment period spans a few days to roughly two weeks after each dose change. At maintenance dose, once the body has settled, many find the GI effects become background noise rather than a daily disruption. That is the trajectory the evidence supports, though individual experience varies, and some people feel it more than others depending on diet, stress and how quickly they are titrated.
Not everyone experiences bloating equally, and several factors reliably make it worse. Meal size is probably the biggest: a stomach that is already emptying more slowly has less tolerance for large volumes of food. Eating to what felt like a normal portion before starting Wegovy can feel genuinely uncomfortable afterwards, and the discomfort often manifests as bloating rather than straightforward nausea.
Fat content matters too. High-fat meals slow gastric emptying independently of semaglutide, so combining both effects compounds the problem. Foods already associated with gas production (beans, lentils, cruciferous vegetables, fizzy drinks, chewing gum) have a similarly amplifying effect. Eating quickly, which means swallowing more air, adds to the picture.
Timing of doses can also play a role. Some people find their bloating peaks in the day or two following their weekly injection. If your injection day falls on a Monday and you have a heavier meal planned that evening, that context is worth knowing ahead of time. Similarly, if you are travelling or celebrating over a long weekend, being aware of when your dose lands and what you are eating around it can take the edge off what would otherwise feel like a mystery.
For a fuller look at how semaglutide interacts with the digestive system, this page on whether semaglutide causes bloating covers the mechanism in more detail, and our guide to Wegovy bloating and gas addresses the specific combination many people find hardest to manage.
No single intervention eliminates bloating on Wegovy, but several changes make a consistent difference. Smaller, more frequent meals reduce the volume the stomach has to process at any one time. Eating slowly (putting cutlery down between mouthfuls, a technique gastroenterologists recommend independently of GLP-1 treatment) reduces swallowed air and gives the stomach time to signal fullness before discomfort sets in.
Staying well hydrated helps move things along and reduces constipation, which can itself amplify bloating. Plain still water is the simplest tool. Fizzy water, despite being calorie-free, contributes directly to gas in the stomach and is worth cutting out for the adjustment period. Peppermint tea has some evidence behind it for general bloating relief and is harmless to try.
Avoiding the foods that reliably cause gas is sensible but does not mean abandoning fibre entirely, adequate fibre prevents constipation, which would make bloating worse. The adjustment is about timing and proportion rather than elimination. If you are finding the bloating difficult to manage and are considering practical strategies for stopping bloating on Wegovy, that page brings together the approaches most commonly found helpful.
One thing to be clear about: these are supportive strategies, not a substitute for clinical guidance. If diet changes do not ease your symptoms after a few weeks, or if the bloating is severe enough to affect your daily life, the right step is to contact your prescriber. Slowing titration, spending longer at a given dose, or other clinical adjustments are all options, but they require a prescriber's input, not a forum thread. For context on what it costs to access clinically supervised treatment, our Wegovy cost page explains what legitimate pricing includes.
Ordinary bloating from Wegovy feels like fullness, distension and gas, uncomfortable, but manageable. There is a different pattern that warrants prompt medical attention: severe, persistent abdominal pain, particularly pain that radiates through to the back, with or without vomiting. In January 2026, the MHRA issued a Drug Safety Update specifically highlighting acute pancreatitis as a known but infrequent risk of GLP-1 medicines, the update was clear that this pain pattern should not be dismissed as ordinary GI side effects. You can read it directly via the MHRA's Yellow Card reporting site, which also allows you or a healthcare professional to report any suspected side effects.
Other symptoms that go beyond normal adjustment (worsening pain after several weeks rather than settling, signs of dehydration from repeated vomiting, or any symptom that feels genuinely alarming) should be assessed by a clinician, not managed at home. Our Wegovy treatment overview covers the full side-effect profile for anyone who wants a broader picture before starting, and our page on stomach bloating specifically addresses the more physical, distension-focused symptoms some people find distinct from the gas and nausea cluster.
If you are thinking about starting Wegovy and want to understand how clinically supervised treatment works at nume (including same-day review by a GPhC-registered prescriber and free next-working-day delivery) check your eligibility through a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.